FrancophonIA/ELRC3.0 huggingface dataset:
English: Riarify is used for maintenance (continuing) treatment in patients whose disease is not adequately controlled despite treatment with a combination of two COPD medicines consisting of a long-acting beta-2 agonist plus either an inhaled corticosteroid or a long-acting muscarinic receptor antagonist.
Maltese: Riarify jintuża għal kura ta' manteniment (regolari) f'pazjenti li l-marda tagħhom ma tkunx ikkontrollata b'mod adegwat minkejja kura b'kombinazzjoni ta' żewġ mediċini COPD li jikkonsistu minn agonista ta' beta-2 li taħdem fit-tul flimkien ma' jew kortikosterojde inalata jew ma' antagonista ta' riċettur muskariniku li taħdem fit-tul.
English: Riarify is available as a liquid in a portable inhaler device.
Maltese: Riarify jiġi bħala likwidu f'apparat inalatur portabbli.
English: In the second study lasting a year, patients treated with Riarify had 20% fewer exacerbations (flareups of symptoms) per year than patients treated with tiotropium (a long-acting muscarinic receptor antagonist).
Maltese: Fit-tieni studju li dam sena, il-pazjenti kkurati bi Riarify kellhom 20 % taħrix inqas (attakki mill-ġdid tas-sintomi) fis-sena minn pazjenti kkurati b'tiotropju (antagonista tar-riċettur muskariniku li taħdem fit-tul).
English: Riarify has been shown to be effective at relieving symptoms of COPD in three main studies involving over 5,500 patients whose symptoms were not controlled well enough either by combinations of two other COPD medicines or by a muscarinic receptor antagonist alone.
Maltese: Riarify intwera li hu effettiv biex itaffi s-sintomi ta' COPD fi tliet studji ewlenin li kienu jinvolvu iktar minn 5 500 pazjent li s-sintomi tagħhom ma kinux ikkontrollati tajjeb biżżejjed minn l-ebda waħda mill-kombinazzjonijiet ta' żewġ mediċini COPD oħrajn jew minn antagonista ta' riċettur muskariniku waħdu.
English: As for all medicines, data on the use of Riarify is continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Riarify hija ssorveljata kontinwament.
English: For the full list of side effects and restrictions with Riarify, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet b'Riarify, ara l-fuljett ta' tagħrif.
English: Patients should be shown how to use the inhaler correctly by a doctor or another healthcare professional, who should also regularly check that the patient's inhalation technique is correct.
Maltese: Il-pazjenti għandhom jintwerew kif jużaw l-inalatur b'mod korrett minn tabib jew minn professjonist filqasam tal-kura tas-saħħa ieħor, li għandhom ukoll jiċċekkjaw regolarment li t-teknika tal-inalazzjoni tal-pazjent tkun korretta.
English: Beclometasone belongs to anti-inflammatory medicines known as corticosteroids.
Maltese: Il-beklometażona tappartjeni għal grupp ta' mediċini antiinfjammatorji magħrufin bħala kortikosterojdi.
English: In this study, Riarify was as effective as tiotropium plus a combination of beclometasone and formoterol at reducing the number of exacerbations.
Maltese: F'dan l-istudju, Riarify kien effettiv daqs tiotropju flimkien ma' kombinazzjoni ta' beklometażona u formoterol biex inaqqas in-numru ta' taħrix.
English: Riarify is a medicine used in adults to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD).
Maltese: Din il-mediċina hija l-istess bħal Trimbow, li diġà hija awtorizzata fl-UE.
English: No major safety concerns have been reported with Riarify, with side effects being manageable and similar to other COPD medicines.
Maltese: Ma ġie rrappurtat l-ebda tħassib maġġuri dwar is-sigurtà b'Riarify, bl-effetti sekondarji li jistgħu jiġu mmaniġġjati u li huma simili għal mediċini oħra tas-COPD.
English: Riarify is effective at reducing the frequency of exacerbations and improving lung function of patients with COPD.
Maltese: Riarify intwera li huwa effettiv biex inaqqas il-frekwenza tat-taħrix u biex itejjeb il-funzjoni tal-pulmun f'pazjenti bis-COPD.
English: EMA/206131/2014 EMEA/V/C/002746
Maltese: EMEA/V/C/002746
English: Vectra Felis (dinotefuran / pyriproxyfen) EMA/206131/2014
Maltese: Vectra Felis (dinotefuran / piriprossifen) EMA/206131/2014
English: Vectra Felis (dinotefuran / pyriproxyfen)
Maltese: Vectra Felis (dinotefuran / piriprossifen)
English: Further information on Vectra Felis can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/vectra-felis.
Maltese: ema.europa.eu/medicines/veterinary/EPAR/vectra-felis.
English: Other information about Vectra Felis
Maltese: Informazzjoni oħra dwar Vectra Felis
English: Vectra Felis acts as an ectoparasiticide.
Maltese: Vectra Felis jaġixxi bħala ektoparassitiċida.
English: Vectra Felis received a marketing authorisation valid throughout the EU on 6 June 2014.
Maltese: Vectra Felis ingħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fis-6 ta' Ġunju 2014.
English: Vectra Felis must not be used in cats or kittens weighing less than 0.6 kg.
Maltese: Vectra Felis ma għandux jintuża fil-qtates jew fil-qtates żgħar li jiżnu inqas minn 0.6 kg.
English: Vectra Felis was as effective as the comparator product and reduced flea counts by 91% over the 84 day study period.
Maltese: Vectra Felis kien effettiv daqs il-prodott komparatur u naqqas l-għadd tal-briegħed b'91 % matul il-perjodu ta' studju ta' 84 jum.
English: The field study involved 129 cats with flea infestations that were treated once a month for three consecutive months either with Vectra Felis or with another spot-on product containing two different substances, fipronil and (S)-methoprene, that control fleas.
Maltese: L-istudju fuq il-post kien jinvolvi 129 qattus b'infestazzjonijiet tal-briegħed li kienu kkurati darba f'xahar għal tliet xhur konsekuttivi b'Vectra Felis jew bi prodott ieħor għall-użu lokalizzat li fih żewġ sustanzi differenti, il-fipronil u l-(S)-metopren, li jikkontrollaw il-briegħed.
English: Dinotefuran is an insecticide which kills insects by acting on receptors (targets) in their nervous system called nicotinic acetylcholine receptors.
Maltese: Id-dinotefuran hija insettiċida li toqtol l-insetti billi taġixxi fuq ir-riċetturi (miri) fis-sistema nervuża tagħhom imsejħa riċetturi nikotiniċi tal-aċetilkolina
English: What are the risks associated with Vectra Felis?
Maltese: X'inhuma r-riskji assoċjati ma' Vectra Felis?
English: The most common side effects with Vectra Felis (which may affect up to 1 in 1000 cats) are a slight scaling of the skin, temporary redness and itching or temporary hair loss at the application site.
Maltese: L-effetti sekondarji l-aktar komuni b'Vectra Felis (li jistgħu jaffettwaw sa qattus 1 minn 1000) huma skalar żgħir tal-ġilda, ħmura temporanja u ħakk jew telf temporanju tax-xagħar fis-sit talapplikazzjoni.
English: Vectra Felis is a veterinary medicine used to treat and prevent flea infestations in cats.
Maltese: Vectra Felis huwa mediċina veterinarja li tintuża għall-kura u għall-prevenzjoni ta' infestazzjonijiet ta' briegħed fil-qtates.
English: How does Vectra Felis work?
Maltese: Kif jintuża Vectra Felis?
English: For a full list of all side-effects reported with Vectra Felis, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati b'Vectra Felis, ara l-fuljett ta' tagħrif.
English: The effectiveness of Vectra Felis against fleas was investigated in a large number of laboratory studies and in one field study.
Maltese: L-effikaċja ta' Vectra Felis kontra l-briegħed kienet investigata f'għadd kbir ta' studji f'laboratorji u fi studju wieħed fuq il-post.
English: The European Medicines Agency decided that Vectra Felis' benefits are greater than its risks and it can be authorised for use in the EU.
Maltese: L-Aġenzija Ewropea għall-Mediċini ddeċidiet li l-benefiċċji ta' Vectra Felis huma akbar mir-riskji tiegħu u li jista' jiġi awtorizzat għall-użu fl-UE.
English: Pyriproxyfen is an insect growth regulator which stops the flea life cycle by causing production of infertile eggs as well as by blocking the development of immature flea stages into adults.
Maltese: Il-piriprossifen huwa regolatur tat-tkabbir tal-insetti li jwaqqaf iċ-ċiklu tal-ħajja tal-briegħed billi jikkawża l-produzzjoni ta' bajd infertili kif ukoll jimblokka liżvilupp tal-istadji tal-briegħed immaturi f'adulti.
English: The need to re-treat cats and the time interval between treatments requires veterinary assessment.
Maltese: In-nies ma għandhomx imissu qtates ikkurati għal tal-anqas tmien sigħat wara l-applikazzjoni talmediċina veterinarja.
English: * adsorbed on aluminium phosphate
Maltese: * adsorbit fuq aluminium phosphate
English: 1 conjugated to protein D (derived from non-typeable Haemophilus influenzae) carrier protein
Maltese: 0.5 milligramma Al3+ 1 konjugat ma' proteina carrier ta' proteina D (derivata minn non-typeable Haemophilus influenzae)
English: --1 1 dose (0.5 ml) contains: Pneumococcal polysaccharide serotype 1* 1
Maltese: --1 doża 1 (0.5 ml) fiha: Polysaccharide pnewmokokkali serotip 1* 1
English: Pneumococcal polysaccharide serotype 18C* 2
Maltese: Polysaccharide pnewmokokkali serotip 18C* 2
English: Pneumococcal polysaccharide serotype 9V* 1
Maltese: Polysaccharide pnewmokokkali serotip 9V* 1
English: Pneumococcal polysaccharide serotype 6B* 1
Maltese: Polysaccharide pnewmokokkali serotip 6B* 1
English: 2 conjugated to tetanus toxoid carrier protein
Maltese: 2 konjugat ma' proteina carrier ta' toxoid tat-tetnu
English: 3 conjugated to diphtheria toxoid carrier protein
Maltese: 3 konjugat ma' proteina carrier ta' toxoid tad-difterite
English: Content Pack size
Maltese: Numru tal-MA
English: 10 pre-filled syringes + 10 needles
Maltese: 10 siringi mimlijin għal-lest + 10 labar siringa 1 mimlija għal-lest + 2 labar
English: 0.5 milligram Al3+
Maltese: 50 siringa mimlijin għal-lest
English: 1 pre-filled syringe + 1 needle
Maltese: Daqs talpakkett siringa 1 mimlija għal-lest
English: Dr Alar Irs (Estonia)
Maltese: Dr Alar Irs (L-Estonja)
English: What is Atacand?
Maltese: X'inhu Atacand?
English: EMEA/CHMP/169828/2010 rev. EMEA/H/A-30/1150
Maltese: EMEA/H/A-30/1150
English: Atacand is also available in the EU under other trade names: Amias, Blopress, Kenzen, Parapres, Racanda and Ratacand.
Maltese: Atacand huwa disponibbli wkoll fl-UE taħt ismijiet kummerċjali oħrajn: Amias, Blopress, Kenzen, Parapres, Racanda u Ratacand.
English: Dr Pieter de Graeff (The Netherlands)
Maltese: Dr Pieter de Graeff (Il-Pajjiżi l-Baxxi)
English: Company responses provided on: 8 October 2009, 12 February 2010 Opinion date:
Maltese: 8 ta' Ottubru 2009, 12 ta' Frar 2010
English: The active substance in Atacand, candesartan cilexetil, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Maltese: Is-sustanza attiva f'Atacand, candesartan cilexetil, hija 'antagonista ta' riċettur ta' anġjotensin II', li jfisser li timblokka l-azzjoni ta' ormon fil-ġisem imsejjaħ anġjotensin II. Anġjotensin II huwa vażokostrittur qawwi (sustanza li traqqaq il-vini tad-demm).
English: For heart failure, the starting dose is 4 mg once a day, which can also be increased at intervals of at least two weeks up to a maximum of 32 mg once daily.
Maltese: Għall-kollass tal-qalb, id-doża tal-bidu hija 4 mg darba kuljum, li tista' tiżdied ukoll f'intervalli ta' millinqas ġimagħtejn sa massimu ta' 32 mg darba kuljum.
English: Co-Rapporteur:
Maltese: Korelatur:
English: • heart failure and impaired left ventricular systolic function as ‘add-on' therapy to ACE inhibitors or when ACE inhibitors are not tolerated.
Maltese: • kollass tal-qalb u funzjoni sistolika indebolita tal-ventrikola tax-xellug bħala kura ‘addizzjonali' għal inibituri ACE jew meta l-inibituri ACE ma jkunux ittollerati.
English: The companies that market these medicines are AstraZeneca and Takeda.
Maltese: Il-kumpaniji li jikkummerċjalizzaw lil dawn il-mediċini huma AstraZeneca u Takeda.
English: Atacand was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Maltese: Famvir ġie identifikat bħala li jeħtieġ armonizzazzjoni mill-Grupp ta' Koordinazzjoni dwar il-Proċeduri Konġunti u Deċentralizzati - tal-Bniedem (CMD(h)).
English: Atacand is authorised in the EU via national procedures.
Maltese: Atacand huwa awtorizzat fl-UE permezz ta' proċeduri nazzjonali.
English: It is also used to treat heart failure in adult patients with impaired left ventricular systolic function who are receiving treatment with ‘angiotensin converting enzyme (ACE) inhibitors' or who cannot be given ACE inhibitors.
Maltese: Tintuża wkoll biex tikkura kollass tal-qalb f'pazjenti adulti b'funzjoni sistolika ventrikulari tax-xellug indebolita li jkunu qegħdin jirċievu kura b'‘inibituri ta' enzim li jikkonverti anġjotensin (ACE)' jew li ma jistgħux jingħataw inibituri ACE.
English: The Committee harmonised the warning on hyperkalaemia (high blood potassium levels) across all Member States' SmPCs.
Maltese: Il-Kumitat armonizza ttwissija dwar iperkalaemija (livelli għoljin ta' potassju fid-demm) madwar l-SmPCs tal-Istati Membri kollha.
English: Some Member States had not approved the 32 mg dose for treating hypertension and there were differences in how heart failure was defined.
Maltese: Xi Stati Membri ma approvawx id-doża ta' 32 mg għall-kura ta' pressjoni għolja u kien hemm differenzi f'kif il-kollass tal-qalb ġie definit.
English: On 16 July 2009, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Atacand in the EU.
Maltese: Fis-16 ta' Lulju 2009, il-Kummissjoni Ewropea irreferiet il-kwistjoni lis-CHMP sabiex jiġu armonizzati lawtorizzazzjonijiet għat-tqegħid fis-suq għal Atacand fl-UE.
English: It must also not be given to women in their second or third trimesters of pregnancy or to patients with severe liver impairment or cholestasis (problems with the elimination of bile).
Maltese: Ma għandux jingħata lil nisa li jkunu fit-tieni jew fit-tielet trimestri tat-tqala jew lil pazjenti b'indeboliment sever tal-fwied jew b'kolestażi (problemi bl-eliminazzjoni tal-likwidu tal-bila).
English: • essential hypertension;
Maltese: • pressjoni għolja essenzjali:
English: The CHMP recommended that Atacand should be used to treat adult patients with:
Maltese: Is-CHMP irrakkomanda li Atacand għandu jintuża biex jikkura pazjent adulti bi:
English: The recommended starting dose for treating hypertension is 8 mg once a day, which can be increased to a maximum of 32 mg once a day, depending on how the patient's blood pressure responds.
Maltese: Id-doża tal-bidu rrakkomandata għall-kura tal-pressjoni għolja hija ta' 8 mg kuljum, li tista' tiżdied għal massimu ta' 32 mg darba kuljum, jiddependi fuq kif tirrispondi l-pressjoni tad-demm tal-pazjent.
English: By blocking the receptors to which angiotensin II normally attaches, candesartan cilexetil stops the hormone having an effect, allowing the blood vessels to widen.
Maltese: Billi jimblokka r-riċetturi li magħhom normalment jeħel l-anġjotensin II, candesartan cilexetil iwaqqaf l-ormon milli jkollu effett, u dan jippermetti lill-vini tad-demm sabiex jitwessgħu.
English: The full EPAR for Darunavir Krka can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: L-EPAR sħiħ għal Darunavir Krka jista' jinstab fuq is-sit elettroniku tal-Aġenzija: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Darunavir Krka is an antiviral medicine used with other HIV medicines to treat patients with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: Darunavir Krka huwa mediċina antivirali li tintuża f'kombinazzjoni ma' mediċini oħra tal-HIV fil-kura ta' pazjenti infettati bil-virus tal-immunodefiċjenza umana tat-tip 1 (HIV-1), virus li jikkawża s-sindromu tal-immunodefiċjenza akkwiżita (AIDS).
English: The active substance in Darunavir Krka, darunavir, is a protease inhibitor.
Maltese: Is-sustanza attiva f'Darunavir Krka, darunavir, hija inibitur tal-proteażi.
English: Darunavir Krka is a ‘generic medicine'.
Maltese: Darunavir Krka huwa “mediċina ġenerika”.
English: This is a summary of the European public assessment report (EPAR) for Darunavir Krka.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Darunavir Krka.
English: Darunavir Krka may be given to adults or children from 3 years of age and weighing at least 15 kg.
Maltese: Darunavir Krka jista' jingħata lill-adulti u lit-tfal minn 3 snin 'il fuq u li jiżnu mill-inqas 15-il kg.
English: The Agency recommended that Darunavir Krka be approved for use in the EU.
Maltese: LAġenzija rrakkomandat li Darunavir Krka jkun approvat għall-użu fl-UE.
English: Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Prezista, and do not need to be repeated for Darunavir Krka.
Maltese: Diġà saru l-istudji fuq il-benefiċċji u r-riskji tas-sustanza attiva fl-użu approvat mal-mediċina ta' referenza, Prezista, u m'hemmx għalfejn jiġu ripetuti għal Darunavir Krka.
English: Because Darunavir Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Peress li Darunavir Krka huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: The company also carried out a study that showed that it is ‘bioequivalent' to the reference medicine.
Maltese: Il-kumpanija wettqet ukoll studju li wera li huwa “bijoekwivalenti” għall-mediċina ta' referenza.
English: Darunavir Krka contains the active substance darunavir.
Maltese: Darunavir Krka fih is-sustanza attiva darunavir.
English: This means that Darunavir Krka contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Prezista.
Maltese: Dan ifisser li Darunavir Krka fih l-istess sustanza attiva u jaħdem bl-istess mod bħall-“mediċina ta' referenza” li hija diġà awtorizzata fl-Unjoni Ewropea (EU) blisem ta' Prezista.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Darunavir Krka has been shown to have comparable quality and to be bioequivalent to Prezista.
Maltese: L-Aġenzija Ewropea għall-Mediċini kkonkludiet li, b'mod konformi mar-rekwiżiti tal-UE, intwera li Darunavir Krka għandu kwalità komparabbli u huwa bijoekwivalenti għal Prezista.
English: Why is Darunavir Krka approved?
Maltese: Għaliex ġie approvat Darunavir Krka?
English: How does Darunavir Krka work?
Maltese: Kif jintuża Darunavir Krka?
English: What are the benefits and risks of Darunavir Krka?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Darunavir Krka?
English: Darunavir Krka does not cure HIV infection or AIDS, but HIV treatment may hold off the damage to the immune system and the development of infections and diseases associated with AIDS.
Maltese: Darunavir Krka ma jfejjaqx l-infezzjoni tal-HIV jew l-AIDS, iżda l-kura tal-HIV tista' tittardja l-ħsara li ssir lis-sistema immunitarja u l-iżvilupp ta' infezzjonijiet u mard assoċjat mal-AIDS.
English: It is not intended to provide practical advice on how to use Darunavir Krka.
Maltese: Dan mhux intiż biex jipprovdi konsultazzjoni prattika dwar l-użu ta' Darunavir Krka.
English: Darunavir Krka, taken in combination with other HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Maltese: Meta Darunavir Krka jittieħed flimkien ma' mediċini oħra ta' kontra l-HIV, inaqqas l-ammont tal-HIV fid-demm u jżommu f'livell baxx.
English: Hypromellose substitution type 2910 (3 mPa·s) Macrogol 4000
Maltese: Hypromellose tip ta' sostitut 2910 (3 mPa·s) Macrogol 4000
English: Date of latest renewal: 27 August 2018
Maltese: Data tal-aħħar tiġdid: 27 t'Awissu 2018
English: Microcrystalline cellulose Crospovidone, type A
Maltese: Microcrystalline cellulose Crospovidone, tip A
English: − Severe renal impairment (GFR < 30 ml/min/1.73 m2).
Maltese: − Indeboliment renali sever (GFR < 30 ml/min/1.73 m2).
English: Erythema multiformeh
Maltese: Eritema multiformih
English: Palpitationsa, oedema peripherala
Maltese: Palpitazzjonijieta, edima periferalia
English: Via Provinciale Schito 131 IT-80058 Torre Annunziata/NA Italy
Maltese: Via Provinciale Schito 131 IT-80058 Torre Annunziata/NA L-Italja
English: Respiratory distress (including pneumonitis and pulmonary oedema) h
Maltese: Distress respiratorju (inkluż pulmonite u edima fil-pulmuni) h
English: - hereditary angioedema.
Maltese: - anġjoedima ereditarja.
English: Dizzinessa,h
Maltese: Sturdamenta,h
English: Impotenceh
Maltese: Impotenzah
English: Aliskiren is a renin inhibitor.
Maltese: Aliskiren huwa inibitur ta' renin.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 16 January 2009
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI/TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: 16 ta' Jannar 2009
English: The incidence of atrial fibrillation was 11.1%, 13.3%, and 11.0% in the combination, aliskiren, and enalapril groups, respectively.
Maltese: L-inċidenza ta' fibrillazzjoni atrijali kienet ta' 11.1%, 13.3%, u 11.0% fil-gruppi mogħtija l-mediċini flimkien, aliskiren, u enalapril, rispettivament.
English: Serum potassium
Maltese: Potassium fis-serum
English: Hyperkalaemiaa, hyponatraemia c, a, h
Maltese: Iperkalimjaa, iponatremja c, a, h
English: (rare: may affect up to 1 in 1,000 pople).
Maltese: (rari: jistgħu jaffettwaw sa persuna waħda minn kull 1,000).
English: Rasilez HCT contains wheat starch.
Maltese: Rasilez HCT fih wheat starch.
English: PVC/polychlorotrifluoroethylene (PCTFE) - Alu blisters Single-packs containing 7, 14, 28, 30, 50, 56, 90 or 98 tablets.
Maltese: Folji PVC/polychlorotrifluoroethylene (PCTFE) - Alu Pakketti b'wieħed li jkun fihom 7, 14, 28, 30, 50, 56, 90 jew 98 pillola.
English: Pharmacotherapeutic group: Agents acting on the renin-angiotensin system; renin inhibitor, ATC code: C09XA52
Maltese: Sustanzi li jaħdmu fuq is-sistema tar-renin-angiotensin; inibituri tarrenin, Kodiċi ATC: C09XA52
English: Rasilez HCT contains lactose.
Maltese: Rasilez HCT fih lactose.
English: Pharmacokinetic interactions with other medicinal products Compounds that have been investigated in clinical pharmacokinetic studies include acenocoumarol, atenolol, celecoxib, pioglitazone, allopurinol, isosorbide-5-mononitrate and hydrochlorothiazide.
Maltese: Interazzjonijiet farmakokinetici ma' prodotti mediċinali oħra Komposti li kienu investigati fi studji ta' farmakokinetika klinika kienu jinkludu acenocoumarol, atenolol, celecoxib, pioglitazone, allopurinol, isosorbide-5-mononitrate u hydrochlorothiazide.
English: Posology as substitution therapy
Maltese: Pożoloġija bħala terapija ta' sostituzzjoni
English: 3 years
Maltese: 3 sentejn
English: Angioedemaa, erythemaa, photosensitivity reactionsh
Maltese: Anġjoedimaa, eritemaa, reazzjonijiet ta' fotosensittivitàh
English: Furosemide and torasemide
Maltese: Furosemide u torasemide
English: P-glycoprotein (P-gp) inhibitors, and other potent P-gp inhibitors (e.g. quinidine), is contraindicated (see section 4.5).
Maltese: glycoprotein (P-gp) qawwija ħafna, u inibituri ta' P-gp qawwija oħrajn (eż. quinidine), huwa kontra-indikat (ara sezzjoni 4.5).
English: High HCTZ use (≥50,000 mg cumulative) was associated with an adjusted OR of 1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC.
Maltese: Użu kbir ta' HCTZ (≥50,000 mg kumulattiva) ġie assoċjat ma' OR aġġustata ta' 1.29 (95 % CI: 1.23-1.35) għal BCC u 3.98 (95 % CI: 3.68-4.31) għal SCC.
English: Noden Pharma DAC D'Olier Chambers 16A D'Olier Street Dublin 2
Maltese: D'Olier Chambers 16A D'Olier Street Dublin 2
English: The final study results indicated a hazard ratio for the primary endpoint of 1.097 in favour of placebo (95.4% Confidence Interval: 0.987, 1.218, 2-sided p=0.0787).
Maltese: Ir-riżultati finali tal-istudji indikaw proporzjon ta' periklu għattragward finali primarju ta' 1.097 favur plaċebo (95.4% Confidence Interval: 0.987, 1.218, 2-sided p=0.0787).